Tom Dorsett, CEO
Tom Dorsett, a native Austinite has been in the healthcare field for 20 years as an entrepreneur and business development executive. Focusing in different areas including health IT, clinical research, and benefits spaces. Tom founded three companies and exited 2 thus far, NuScribe and ePatientFinder. Tom continues to challenge himself by creating innovative solutions across the healthcare spectrum that have a positive effect on patients.
In 2003 Tom founded NuScribe and was its Chief Executive Officer. A provider of cloud-based, voice recognition driven documentation systems for physicians. NuScribe was the first such system to be provided online. Ultimately the platform evolved into the first HIPAA compliant secure messaging system coupled with a social networking platform which was called iMedicor.
In 2006 NuScribe was acquired by Vemics, a provider of real-time video, voice and data
conferencing solutions and continuing education programs.
In 2013 Tom founded ePatientFinder and was its Chief Executive Officer. ePatientFinder provided a platform that connects patients with clinical research opportunities through their own trusted physicians. By leveraging a nationwide network of partner clinics, ePatientFinder is able to educate physicians on pharma client’s trial opportunities. ePatientFinder raised $15M through strategic partners LabCorp (NYSE: LH) and Allscripts (NASDAQ: MDRX). ePatientFinder was acquired in 2018 by Elligo Life Sciences, a contract research organization.
In 2018 Tom and Dr. Siva Mohan founded RazorMetrics. Tom has the role of Chief Executive Officer. RazorMetrics was created to leverage everything mastered through building ePatientFinder including patient and physician engagement techniques. RazorMetrics lowers drug spend for self-funded employers and health plans. This is accomplished through a technology platform that has been built by the organization from the ground up that facilitates a unique engagement model. RazorMetrics has succeeded in conveying over partnerships with both LabCorp and Allscripts which complements a growing number of other strategic relationships.